AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2025
May 14, 2025
30751_dirs_2025-05-13_e056705a-bef7-4944-b120-bc4e34731831.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2025-05-09
Reporting Person: Mulligan Seamus (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-09 | Ordinary Shares | P | 80684 | $98.1046 | Acquired | 80684 | Indirect |
| 2025-05-09 | Ordinary Shares | P | 19216 | $98.9112 | Acquired | 99900 | Indirect |
| 2025-05-09 | Ordinary Shares | P | 100 | $99.71 | Acquired | 100000 | Indirect |
| 2025-05-12 | Ordinary Shares | P | 1621 | $102.9991 | Acquired | 101621 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 1176106 | Direct |
Footnotes
F1: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $97.56 to $98.5542. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.
F2: Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family.
F3: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $98.56 to $99.47. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.
F4: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $102.97 to $103.00. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.